AngioChem Receives US Patent For Angiopep-2

AngioChem’s first patent has been granted by the US Patent and Trademark office. US Patent Number 7557182 is entitled to Aprotinin polypeptides for transporting a compound across the blood-brain barrier, and covers the Angiopep-2 EPiC peptide and conjugates, including ANG1005.

AngioChem’s lead drug candidate ANG1005, is currently being evaluated in two distinct phase I and II clinical trials for cancers of the brain.

AngioChem is a clinical-stage biotechnology company. It is engaged in the discovery and development of new drugs that are capable of crossing the blood-brain barrier to treat brain diseases and related disorders, including brain cancer, cancer metastases, neurodegenerative and metabolic diseases.